Capivasertib
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Capivasertib
Oct 20, 2024, 19:09 |
Insight
Paolo Tarantino: Precision medicine for HR+ metastatic breast cancer: from hope to reality in little more than 5 years
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared on LinkedIn: “Precision medicine for HR+…
Aug 30, 2024, 13:53 |
Blog
Maryam Lustberg: Guide decision making between ESR1 vs PI3K targeting
Maryam Lustberg shared a post on X by Mridula George adding: "The question of sequencing…
Jun 23, 2024, 13:08 |
Drugs
Capivasertib is now approved in EU for HR+/HER2- breast cancer
Paolo Tarantino shared a post on X: "Capivasertib is now approved in EU for the…
Jun 23, 2024, 10:53 |
Blog
Breaking Science in Breast Cancer with Hope Rugo - ESMO
ESMO shared a post on LinkedIn: "For ESMO members: Breaking Science in Breast Cancer. Hope Rugo…
Jun 13, 2024, 03:19 |
Drugs
Amol Akhade: Everolimus vs Alpelisib vs Capivasertib
Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X: “Everolimus vs…
May 18, 2024, 08:47 |
Blog
Elisa Agostinetto: At ESMO Breast24, Hope Rugo presents results of CAPItello-291
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter: ''At…
Apr 25, 2024, 15:40 |
Blog
BioTrinity 2024 in the City of London - The Institute of Cancer Research
The Institute of Cancer Research shared a post on LinkedIn: "Calling companies and potential partners…
Mar 27, 2024, 10:07 |
Insight
Piotr Wysocki: No benefit of continuing CDK4/6i beyond progression in advanced ER+/HER2- breast cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 23, 2024, 04:35 |
Insight
Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?
Piotr Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital, recently…
Jan 7, 2024, 15:14 |
Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Dec 14, 2023, 16:23 |
Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Nov 21, 2023, 14:18 |
Drugs
5 new drug indications by FDA Oncology in the last 10 days - Oncology Brothers
Quoting Oncology Brothers on X/Twitter: "What just happened? 5 new drug indications by FDA Oncology…
Nov 19, 2023, 17:20 |
Drugs
Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter: “Capivasertib is now…
All:
13
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube